Gainplan LLC Acquires 9,962 Shares of Nektar Therapeutics $NKTR

Gainplan LLC grew its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 199.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,962 shares of the biopharmaceutical company’s stock after purchasing an additional 9,962 shares during the quarter. Gainplan LLC’s holdings in Nektar Therapeutics were worth $1,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in NKTR. BNP Paribas Financial Markets grew its stake in Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the period. KBC Group NV acquired a new position in Nektar Therapeutics in the first quarter valued at approximately $52,000. Headlands Technologies LLC acquired a new position in Nektar Therapeutics in the second quarter valued at approximately $65,000. State of Wyoming bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $67,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $68,000. Institutional investors own 75.88% of the company’s stock.

Insider Activity at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 5,681 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $70.00, for a total transaction of $397,670.00. Following the completion of the sale, the insider directly owned 9,756 shares of the company’s stock, valued at approximately $682,920. This trade represents a 36.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Howard W. Robin sold 10,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.32, for a total value of $603,200.00. Following the sale, the chief executive officer owned 65,045 shares in the company, valued at $3,923,514.40. This trade represents a 13.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 21,862 shares of company stock worth $1,379,205. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $73.09 on Thursday. The stock has a market capitalization of $2.47 billion, a PE ratio of -8.68 and a beta of 1.14. Nektar Therapeutics has a 52 week low of $21.60 and a 52 week high of $109.00. The stock has a 50 day moving average price of $66.04 and a two-hundred day moving average price of $67.40.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.The firm had revenue of $10.86 million for the quarter, compared to analyst estimates of $10.69 million. Research analysts forecast that Nektar Therapeutics will post -9.37 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on NKTR shares. Wedbush lowered their price objective on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, May 11th. Citigroup increased their target price on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. Piper Sandler lifted their price target on shares of Nektar Therapeutics from $105.00 to $192.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, BTIG Research upped their price objective on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Nektar Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $150.00.

Nektar Therapeutics Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.